Association analysis of the DRD4 and COMT genes in methamphetamine abuse

American Journal of Medical Genetics - Neuropsychiatric Genetics

Volumn 129 B, Issue 1, 2004, Pages 120-124

  Li, Tao ^a,d   Chen, Chi Ken ^b   Hu, Xun ^a   Ball, David ^a   Lin, Shih Ku ^c   Chen, Wai ^a   Sham, Pak C ^a   Loh, El Wui ^a   Murray, Robin M ^a   Collier, David A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Association; Dopamine system; Epistatic gene gene interaction; Methamphetamine; Substance abuse

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE 4 RECEPTOR; METHAMPHETAMINE; METHIONINE; VALINE;

ADULT; ARTICLE; CASE CONTROL STUDY; COMT GENE; CONTROLLED STUDY; DOPAMINE RELEASE; DRD4 GENE; DRUG ABUSE; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RACE DIFFERENCE; RECEPTOR GENE; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TAIWAN;

ADOLESCENT; ADULT; ALLELES; AMINO ACID SUBSTITUTION; AMPHETAMINE-RELATED DISORDERS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; CENTRAL NERVOUS SYSTEM STIMULANTS; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; METHAMPHETAMINE; MIDDLE AGED; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; TAIWAN;

EID: 3343003563     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Betz C, Mihalic D, Pinto ME, Raffa RB. 2000. Could a common biochemical mechanism underlie addictions? J Clin Pharm Ther 25:11-20.
2. Braver TS, Barch DM, Cohen JD. 1999. Cognition and control in schizophrenia: A computational model of dopamine and prefrontal function. Biol Psychiatry 46:312-328.
3. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ, O'Donovan MC. 2003. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 73:152-161.
4. Chen CK, Hu X, Lin SK, Sham PC, Loh EW, Li T, Murray RM, Ball D. 2004. Association analysis of dopamine D2-like receptor genes and methamphetamine abuse. Psych Gen (in press).
5. Crabbe JC. 2002. Genetic contributions to addiction. Annu Rev Psychol 53:435-462.
6. D'Souza UM, Russ C, Tahir E, Browes C, Mill J, McGuffin P, Asherson PJ, Craig IW. 2002. Functional effects of a tandem duplication popymorphism in the 5′ flanking region of the DRD4 gene. Am J Med Genet (Neuropsychiatric Genet) 114:880.
7. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D, Bennett ER, Nemanov L, Katz M, Belmaker RH. 1996. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet 12:78-80.
8. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. 2001. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917-6922.
9. Ernst T, Chang L, Leonido-Yee M, Speck O. 2000. Evidence for long-term neurotoxicity associated with methamphetamine abuse: An H-MRS study. Neurology 54:1344-1349.
10. Franke P, Nothen MM, Wang T, Knapp M, Lichtermann D, Neidt H, Sander T, Propping P, Maier W. 2000. DRD4 exon III VNTR polymorphism-susceptibility factor for heroin dependence? Results of a case-control and a family-based association approach. Mol Psychiatry 5:101-104.
11. Golstein RZ, Volkow ND. 2002. Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642-1652.
12. Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J, Salonen JT, Ryynanen OP, Koulu M, Karvonen MK, Pohjalainen T, Syvalahti E, Hietala J, Tiihonen J. 2000. Lack of association between the functional variant of the catechol-O-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior. Am J Med Genet 96:348-352.
13. Hoda F, Nicholl D, Bennett P, Arranz M, Aitchison KJ, al-Chalabi A, Kunugi H, Vallada H, Leigh PN, Chaudhuri KR, Collier DA. 1996. Related articles, links [abstract] no association between Parkinson's disease and low-activity alleles of catechol-O-methyltransferase. Biochem Biophys Res Commun 228:780-784.
14. Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H, Ebstein RP. 2000. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 96:599-603.
15. Hutchison KE, McGeary J, Smolen A, Bryan A, Swift RM. 2002. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 21:139-146.
16. Ishiguro H, Haruo Shibuya T, Toru M, Saito T, Arinami T. 1999. Association study between high and low activity polymorphism of catechol-O-methyltransferase gene and alcoholism. Psychiatr Genet 9: 135-138.
17. Jentsch JD, Taylor JR. 1999. Impulsivity resulting from frontostriatal dysfunction in drug abuse: Implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berlin) 146:373-390.
18. Karoum F, Chrapusta SJ, Egan MF. 1994.3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: Reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 63:972-979.
19. Koob GF, Nestler EJ. 1997. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 9:482-497.
20. Kornetsky C, Mirsky AF, Kessler EK, Dorff JE. 1959. The effects of dextroamphetamine on behavioral deficits produced by sleep loss in humans. J Pharmacol Exp Ther 127:46-50.
21. Kosten TR, Markou A, Koob GF. 1998. Depression and stimulant dependence: Neurobiology and pharmacotherapy. J Nerv Ment Dis 186: 737-745.
22. Kotler M, Cohen H, Segman R, Gritsenko I, Nemanov L, Lerer B, Kramer I, Zer-Zion M, Kletz I, Ebstein RP. 1997. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry 2:251-254.
23. Li T, Zhu ZH, Liu X, Hu X, Zhao J, Sham PC, Collier DA. 2000. Association analysis of polymorphisms in the DRD4 gene and heroin abuse in Chinese subjects. Am J Med Genet 96:616-621.
24. Macciardi F. 2003. Multiple testing in genetic association studies: To correct or not to correct. Am J Med Genet 122B:31.
25. Martinetti M, Dugoujon JM, Tinelli C, CiprianiA, Cortelazzo A, Salvaneschi L, Casali L, Semenzato G, Cuccia M, Luisetti M. 2000. HLA-Gm/kappam interaction in sarcoidosis. Suggestions for a complex genetic structure. Eur Respir J 16:74-80.
26. 158-met genotype and individual variation in the brain response to amphetamine. PNAS 100:6186-6191.
27. Nyholt DR. 2001. Genetic case-control association studies-correcting for multiple testing. Hum Genet 109(5):564-567.
28. Ricaurte GA, Schuster CR, Seiden LS. 1984. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res 303:359-364.
29. Rogers RD, Everitt BJ, Baldacchino A, Blackshaw AJ, Swainson R, Wynne K, Baker NB, Hunter J, Mcarthy T, London M, Deakin JFW, Sahakian BJ, Robbins TW. 1999. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depeleted normal volunteers: Evidence for monoaminergic mechanisms. Neuropsychopharmacology 20:322-339.
30. Seaman MI, Fisher JB, Chang F, Kidd KK. 1999. Tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4). Am J Med Genet 88:705-709.
31. Sell LA, Morris J, Bearn J, Frackowiak RS, Friston KJ, Dolan RJ. 1999. Activation of reward circuitry in human opiate addicts. Eur J Neurosci 11:1042-1048.
32. Shaikh S, Collier DA, Kerwin RW, Pilowsky LS, Gill M, Xu WM. 1993. Thornton A. Dopamine D4 receptor subtypes and response to clozapint. Lancet 341:116.
33. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler MY, Shinar E, Beckmann JS, Yakir B, Risch N, Zak NB, Darvasi A. 2002. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71:1296-1302.
34. Sim T, Simon SL, Domier CP, Richardson K, Rawson RA, Ling W. 2002. Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. J Addict Dis 21:75-89.
35. Simon SL, Domier CP, Sim T, Brethen P, Richardson K, Rawson R, Ling W. 2002. Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 21:61-74.
36. Tiihonen J, Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J, Salonen JT, Ryynanen OP, Koulu M, Karvonen MK, Pohjalainen T, Syvalahti E, Hietala J. 1999. Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry 4:286-289.
37. Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, Meyer JM, Toomey R, Faraone SV, Eaves L. 1996. Genetic influences on DSM-III-R drug abuse and dependence: A study of 3,372 twin pairs. Am J Med Genet 67:473-477.
38. Tsuang MT, Bar JL, Harley RM, Lyons MJ. 2001. The Harvard Twin Study of substance abuse: What we have learned. Harv Rev Psychiatry 9:267-279.
39. Uhl GR, Vandenbergh DJ, Rodriguez LA, Miner L, Takahashi N. 1998. Dopaminergic genes and substance abuse. Adv Pharroacol 42:1024-1032.
40. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM. 1997. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 74:439-442.
41. Vandenbergh DJ, Rodriguez LA, Hivert E, Schiller JH, Villareal G, Pugh EW, Lachman H, Uhl GR. 2000. Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: No interaction with functional alleles of the catechol-O-methyltransferase (COMT) gene. Am J Med Genet 96:678-683.
42. Villemagne V, Yuan J, Wong DF, Dannals RF, Hatzidimitriou G, Mathews WN, Ravert HT, Musachio J, McCann UD, Ricaurte GA. 1998. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: Evidence from [C-11]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18:419-427.
43. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN. 2001. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382.
44. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. 2002. Role of dopamine, the frontal cortex and memory circuits in drug addiction: Insight from imaging studies. Neurobiol Learn Mem 78:610-624.
45. Wang T, Franke P, Neidt H, Cichon S, Knapp M, Lichtermann D, Maier W, Propping P, Nothen MM. 2001. Association study of the low-activity allele of catechol-O-methyltransferase and alcoholism using a family-based approach. Mol Psychiatry 6:109-111.
46. Wise RA. 2000. Addiction becomes a brain disease. Neuron 26:27-33.
47. Zhao JH, Sham PC. 2002. Faster haplotype frequency estimation using unrelated subjects. Hum Hered 53:36-41.
48. Zhao JH, Curtis D, Sham PC. 2000. Model-free analysis and permutation tests for allelic associations. Hum Hered 50:133-139.